scholarly journals MicroRNA expression in animal models of amyotrophic lateral sclerosis and potential therapeutic approaches

2022 ◽  
Vol 17 (4) ◽  
pp. 728
Author(s):  
PhilipV Peplow ◽  
Bridget Martinez
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
James C. Dodge ◽  
Jinlong Yu ◽  
S. Pablo Sardi ◽  
Lamya S. Shihabuddin

AbstractAberrant cholesterol homeostasis is implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS), a fatal neuromuscular disease that is due to motor neuron (MN) death. Cellular toxicity from excess cholesterol is averted when it is enzymatically oxidized to oxysterols and bile acids (BAs) to promote its removal. In contrast, the auto oxidation of excess cholesterol is often detrimental to cellular survival. Although oxidized metabolites of cholesterol are altered in the blood and CSF of ALS patients, it is unknown if increased cholesterol oxidation occurs in the SC during ALS, and if exposure to oxidized cholesterol metabolites affects human MN viability. Here, we show that in the SOD1G93A mouse model of ALS that several oxysterols, BAs and auto oxidized sterols are increased in the lumbar SC, plasma, and feces during disease. Similar changes in cholesterol oxidation were found in the cervical SC of sporadic ALS patients. Notably, auto-oxidized sterols, but not oxysterols and BAs, were toxic to iPSC derived human MNs. Thus, increased cholesterol oxidation is a manifestation of ALS and non-regulated sterol oxidation likely contributes to MN death. Developing therapeutic approaches to restore cholesterol homeostasis in the SC may lead to a treatment for ALS.


2019 ◽  
Vol 3 ◽  
pp. 115-116
Author(s):  
Garofalo D ◽  
Re D ◽  
Kaye W ◽  
Brennan K ◽  
Kioumourtzoglou M ◽  
...  

2019 ◽  
pp. 243-252
Author(s):  
Albert C. Ludolph

Amyotrophic lateral sclerosis (ALS) is among the most severe neurological conditions which leaves the patient in a speechless (deefferentiated) state. Advocacy is yielded to give patients a voice and to recognize patient’s actual preferences and needs. The chapter reviews the most important levels where advocacy is required: the affected families, professionals, the public, and health and science politics. When advocacy is performed in a considerate and thoughtful manner, patient’s coping mechanisms can be activated and quality of life can be secured to facilitate life in dignity; caregiver’s burden can be substantially reduced. For the public and scientific world, advocacy may lead to more efficient therapeutic approaches and allows for patient-centred care.


2008 ◽  
Vol 40 (6) ◽  
pp. 568-577 ◽  
Author(s):  
Thomas S. Guillot ◽  
Seneshaw A. Asress ◽  
Jason R. Richardson ◽  
Jonathan D. Glass ◽  
Gary W. Miller

Sign in / Sign up

Export Citation Format

Share Document